Upon completion of the educational activity, participants should be able to:

Session 1-  Unusual/Infiltrative Cardiomyopathies – Amyloid, HCM

• Outline the challenges of ICD decision making in cardiac sarcoidosis.
• Provide overview of genetic cardiomyopathies.
• Define current options and issues in medical treatment of infiltrative diseases and selection of appropriate therapies.
• Review approaches to genetic counseling in patients with cardiomyopathies and their family members.

Session 2 -  Women's Health

• Apply age and time-since-menopause ("timing hypothesis") to cardiovascular risk when considering menopausal hormone therapy.
• Recognize and initiate GDMT for peripartum cardiomyopathy, including which HF medications are safe versus contraindicated across pregnancy and lactation.
• Select and sequence the appropriate multimodality imaging tests to establish the underlying mechanism of MINOCA.
• Identify the sex-specific procedural complications women face and the modifiable strategies that reduce them.

Session 3 -  Acute Pulmonary Embolism: Redefining Risk and Improving Patient Care

• Employ updated guideline-recommended risk stratification framework for classifying patients with acute pulmonary embolism across the full continuum of risk.
• Explain the role of Pulmonary Embolism Response Teams (PERT) and identify clinical situations in which multidisciplinary consultation may be appropriate.
• Compare the available treatment approaches for acute pulmonary embolism as well as their evidence, including anticoagulation, systemic thrombolysis, catheter-directed therapies, and mechanical thrombectomy.

Session 4 -  Prevention

• Identify and apply key changes from recent cardiovascular dyslipidemia and hypertension guidelines, including updated cardiovascular risk assessment, blood pressure and lipid treatment targets, use of Lp(a)/ApoB, and practical lipid-lowering strategies.
• Distinguish key changes in atrial fibrillation (AF) contemporary guidelines from prior recommendations and describe their implications for risk-factor modification, rhythm control, stroke prevention, and device-detected AF.
• Describe the evolving role of CAC and CCTA in cardiovascular disease prevention and management and apply imaging findings to inform risk assessment management decisions.

Session 5 -  It’s all about what you don’t see- Case-based discussion of ANOCA

• Understand how to evaluate for non obstructive causes of chest pain syndrome.
• Develop an understanding of the management options for non obstructive causes of chest pain syndrome.

Session 6 -  Heart Failure Management

• Identify patients at elevated baseline risk for cancer therapy-related cardiovascular toxicity.
• Increase understanding of MRI myocardial tissue characterization and the use of coronary CT to evaluate ischemic etiology in new-onset HFrEF.
• Describe the four pillars of guideline-directed medical therapy (GDMT) for HFrEF and strategies for rapid initiation and titration.
• Recognize the need for early referral for advanced heart failure therapies and understand patient-selection principles for durable LVAD and heart transplantation.

Session 7 -  Stump the Expert

• Identify appropriate candidates for left atrial appendage occlusion (LAAO) by considering thromboembolic risk, anticoagulation tolerance, and need for concomitant atrial fibrillation (AF) ablation.
• Discuss the role of pre- and post-LAAO imaging and recognize clinically important findings, including device-related thrombus and peri-device leak.
• Implement safe rhythm control after LAAO, including cardioversion and AF ablation, with appropriate imaging in patients unable to tolerate anticoagulation.

Commercial Support 
There is no commercial support for this activity.